细胞外膀衍生非编码RNAs:重塑心力衰竭的关键调解者
Jiayi Zhao1,2, Huang Huang1,2
1Department of Cardiovascular Surgery, The First Affiliated Hospital of Nanchang University, Nanchang 330006, China.
Current issues in molecular biology
|September 27, 2024
概括
细胞外囊泡非编码RNAs (EV-ncRNAs) 显示出对诊断和治疗心力衰竭 (HF) 的前景. 这些分子,包括微RNA和循环RNA,是细胞通信和HF进展的关键,提供了新的治疗策略.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 心脏病学 心脏病学
背景情况:
- 心力衰竭 (HF) 是一个关键的全球健康问题,治疗治疗方法有限.
- 细胞外囊泡 (EVs) 对于细胞间通信至关重要,运输RNA,DNA和蛋白质等生物分子.
- 非编码RNAs (ncRNAs),包括microRNAs (miRNAs),长ncRNAs (lncRNAs) 和圆形RNAs (circRNAs),在EV中发现并影响HF病理生理学.
研究的目的:
- 审查心力衰竭中EV-ncRNAs的机制.
- 突出不同表达的miRNA和circRNA在心血管疾病中的诊断潜力.
- 总结EV工程的进展,用于HF诊断和治疗.
主要方法:
- 文献综述侧重于高频率的EV-ncRNA机制.
- 对miRNA和circRNA作为心血管疾病生物标志物的研究分析.
- 检查最近关于基于EV的诊断和治疗策略的研究HF.
主要成果:
- EV-ncRNAs在受体细胞中调节HF方面发挥着重要作用.
- 在EV中差异表达的miRNAs和circRNAs显示出作为HF生物标志物的潜力.
- 电动汽车可以设计为有针对性的交付,为HF提供新的治疗方法.
结论:
- EV-ncRNAs代表了对心力衰竭的诊断和治疗的一个有希望的前沿.
- 进一步研究电动汽车工程对于开发有效的高频疗法至关重要.
- 了解EV-ncRNA相互作用为心血管疾病机制提供了新的见解.
更多相关视频
09:37Permanent Ligation of the Left Anterior Descending Coronary Artery in Mice: A Model of Post-myocardial Infarction Remodelling and Heart Failure
Published on: December 2, 2014
27.8K
10:21Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
Published on: June 14, 2016
10.0K
相关概念视频
01:29Heart Failure II: Pathophysiology
3
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
3
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
396
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
396
01:22Heart Failure Drugs: Diuretics
349
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
349
01:30Heart Failure V: Medical Management
2
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
2
01:27Heart Failure I: Introduction
2
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
2